2018 American Transplant Congress
Modified Protocol for ABO-Incompatible Living Donor Liver Transplantation with Rituximab and Intravenous Immunoglobulin without Plasma Exchange
Center for Liver Cancer, National Cancer Center, Il-san Donggu, Goyang, Republic of Korea.
Purpose: Since a variety of desensitization strategies including rituximab, intravenous immunoglobulin (IVIG), and plasma exchange (PE) have been introduced, the survival and outcomes of recipients…2018 American Transplant Congress
Effect of HLA Antibodies on Graft Survival in Adult Live Donor Liver Transplantation
The relevance of HLA antibodies in liver transplantation is currently being re-evaluated. While hyperacute rejections are not an issue, antibody effects on long-term outcomes are…2018 American Transplant Congress
Impact of De Novo DSA (DnDSA) on Outcomes in HLA-Sensitized (HS) Patients Transplanted after IVIG + Rituximab Desensitization (DES)
Introduction: Highly-HLA sensitized patients (HS) with donor specific antibodies (DSA) at transplant are at risk for Type 1 ABMR. However, the incidence of Type 2…2018 American Transplant Congress
Pre-Emptive Rituximab and Intravenous Immunoglobulin (IVIg) Fail to Prevent Rejection in Kidney Transplant Recipients (KTx) with Donor Specific Antibodies (DSA)
Columbia University, New York, NY.
Introduction:IVIg and Rituximab have been used successfully to improve transplantation rates in sensitized patients. DSA detected by Flow crossmatch (FXM+) or Luminex® at time of…2018 American Transplant Congress
IVIG Induction May Be Helpful in Highly Sensitized Patients after Heart Transplantation
Cedars Sinai Medical Center, Los Angeles.
Purpose: Strategies for sensitized patients undergoing heart transplant include post-op anti-thymocyte globulin (ATG) induction therapy as well as intravenous immunoglobulin (IVIG). We sought to assess…2018 American Transplant Congress
Acute Antibody Mediated Rejection Treatment Impact on Class I and Class II Anti-HLA Antibodies in Pediatric Kidney Transplant Recipients
Purpose: Characterize class I and class II donor specific antibodies (DSA) response to acute antibody mediated rejection (AMR) treatment in pediatric kidney transplant recipients (KTR).Methods:…2018 American Transplant Congress
Long Term IVIG Infusions for Treatment of Chronic Antibody Mediated Rejection in Pediatric Kidney Transplant Recipients
Objectives: The emergence of donor specific antibodies (DSA) after kidney transplantation (Tx) is associated with lower graft survival. The benefit of using intravenous gamma globulin…2018 American Transplant Congress
Efficacy and Safety of Acute Antibody Rejection Treatment in Pediatric Kidney Transplant Recipients
Purpose: Evaluate the efficacy and safety of acute antibody mediated rejection (AMR) treatment modalities in pediatric kidney transplant recipients (KTR).Methods: A single-center retrospective chart review…2017 American Transplant Congress
Experience with the Bacterial Enzyme IdeS (IgG Endopeptidase) for Desensitization of Highly-HLA Sensitized (HS) Kidney Allograft Recipients.
Donor specific antibodies (DSA) create an impenetrable immunologic barrier to transplantation. Current rx aimed at modification of DSAs are not effective in the most HS…2017 American Transplant Congress
Update of a Placebo-Controlled Trial of C1 Esterase Inhibitor for Prevention of Antibody Mediated Rejection (ABMR) in Highly-HLA Sensitized Patients.
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA
INTRODUCTION: Desensitization (DES) strategies focus primarily on antibody reduction using IVIG, rituximab ± PLEX to prevent DSA-induced ABMR and rebound B-cell activity. Pathologic features of…
American Transplant Congress abstracts